Browsed by
Tag: IPO

Tarsus Pharmaceuticals Seeks $80 Million In U.S. IPO (Pending:TARS)

Tarsus Pharmaceuticals Seeks $80 Million In U.S. IPO (Pending:TARS)

Quick Take

Tarsus Pharmaceuticals (TARS) has filed to raise $80 million in an IPO of its common stock, according to an S-1 registration statement.

The company is developing treatments for Demodex blepharitis and other ophthalmic conditions.

TARS has produced enviable efficacy trial results for its lead candidate and the IPO is reasonably priced, so for life science investors with a hold time frame of 18 to 24 months, the IPO is worth considering.

Company & Technology

Irvine, California-based Tarsus was founded to advance a portfolio of treatment options for various eye conditions caused by mites and other parasites.

Management is headed by co-founder, president and CEO Mr. Bobak Azamian, M.D., Ph.D., who has been with the firm since and was previously co-founder, CEO and CMO of Metavention, a company seeking to treat diabetes and other metabolic diseases.

Below is a brief overview video of Demodex Blepharitis:

Source: Nattawut Wanumkarng

The company’s lead candidate is TP-03, a treatment being developed for three indications related to the Demodex mite.

Management expects to provide top line data results for its Phase 2b/3 Saturn-1 trial in 2021, as well as initiate a Phase 3 Saturn-2 trial in 2021.

Below is the current status of the company’s drug development pipeline:

Source: Company S-1 Filing

Investors in the firm have invested at least $63.4 million and include Horowitz Limited Partnership, Vivo Capital, Flying L Investments, Frazier Life Sciences, Visionary Venture Fund, RTW Investments and Cormorant Asset Management.

Market & Competition

According to a 2018 market research report by Transparency Market Research, the global incidence of patients with increased ocular disorders is increasing due to the rise in the elderly population.

In a recent survey report in the U.S., 37% – 47% of patients ‘were diagnosed with signs of blepharitis.’

Related conditions to blepharitis include acne rosacea,

Read the rest
Tarsus Pharmaceuticals Proposes Terms For $80 Million IPO

Tarsus Pharmaceuticals Proposes Terms For $80 Million IPO

Tarsus Pharmaceuticals (TARS) intends to raise $80 million in an IPO of its common stock, according to an S-1 registration statement.

Irvine, California-based Tarsus was founded to advance a portfolio of treatment options for various eye conditions caused by mites and other parasites.

Management is headed by co-founder, president and CEO Mr. Bobak Azamian, M.D., Ph.D., who has been with the firm since and was previously co-founder, CEO and CMO of Metavention, a company seeking to treat diabetes and other metabolic diseases.

Below is a brief overview video of Demodex Blepharitis:

Source: Nattawut Wanumkarng

The company’s lead candidate is TP-03, a treatment being developed for three indications related to the Demodex mite.

Management expects to provide top line data results for its Phase 2b/3 Saturn-1 trial in 2021, as well as initiate a Phase 3 Saturn-2 trial in 2021.

Below is the current status of the company’s drug development pipeline:

tarsuspipe

Source: Company S-1 Filing

Investors in the firm have invested at least $63.4 million and include Horowitz Limited Partnership, Vivo Capital, Flying L Investments, Frazier Life Sciences, Visionary Venture Fund, RTW Investments and Cormorant Asset Management.

According to a 2018 market research report by Transparency Market Research, the global incidence of patients with increased ocular disorders is increasing due to the rise in the elderly population.

In a recent survey report in the U.S., 37% – 47% of patients ‘were diagnosed with signs of blepharitis.’

Related conditions to blepharitis include acne rosacea, Lyme disease and malaria, all areas in which the firm is pursuing treatments.

However, drugs with significant side effects or lengthy procedures can hamper market adoption.

Major competitive vendors that provide or are developing treatments include:

  • Azura Ophthalmics
  • Aperta Biosciences
  • Eyevance Pharmaceuticals
  • Formosa Pharmaceuticals
  • Hovione Scientia
  • Nicox SA (NICXF)
  • Novaliq GmbH
  • Premark Pharma
  • Quorum Innovations

Tarsus’s recent financial

Read the rest
The 3Q20 IPO Market’s Law Firm Leaderboard

The 3Q20 IPO Market’s Law Firm Leaderboard

The 3Q20 was a record-breaking quarter for IPO activity, with 81 IPOs raising $28.5 billion. Soaring peer multiples and IPO enthusiasm caused activity to increase significantly from the 3Q19, when 39 IPOs raised $10.8 billion. Healthcare was the most active sector, as larger health services providers joined the steady stream of biotechs, followed by tech which saw a surge of activity in September. With every IPO requiring at least two legal firms, one for issuers and one for underwriters (and some hiring as many as seven), the 3Q20 saw 216 legal engagements (414 including SPACs) with 72 law firms.

View our Report on The Most Active Legal Firms of the 3Q20 IPO MarketPDF

To read the entire report, sign up for a free trial of IPO Pro, the platform that gives you all of the IPO information you need, all in one place.

Start a Free Trial of IPO Pro

Read Renaissance Capital’s other quarterly publications:

The article The 3Q20 IPO Market’s Law Firm Leaderboard originally appeared on IPO investment manager Renaissance Capital’s web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital’s research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital’s Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source Article Read the rest

Blackstone-Backed Finance of America Is Set for IPO

Blackstone-Backed Finance of America Is Set for IPO

Consumer-lending platform and

Blackstone Group Inc.


BX 0.46%

portfolio company Finance of America Equity Capital LLC is set to go public with a valuation of $1.9 billion through a blank-check merger, this year’s hottest way to list shares, according to people familiar with the matter.

Finance of America is set to merge with the special-purpose acquisition company, or SPAC,

Replay Acquisition Corp.


RPLA -0.58%

, the people said. In conjunction with the merger, institutional investors will also make a private investment of $250 million in the company. In all, the deal will leave the consumer lender’s founder and funds managed by Blackstone with a 70% ownership stake.

SPACs are all the rage in 2020, quickly having become a favored way for companies to go public in a year when initial public offerings are hotter than ever. Their popularity is a sign that there is more demand for newly listed companies than there are companies going public. So far this year, companies have raised more than $109 billion going public in the U.S., surpassing every other full year on record, according to Dealogic, whose data go back to 1995. SPACs have accounted for almost half of that total.

The sole purpose of SPACs, which are also known as blank-check companies, is to raise money to acquire a private target and take it public. Founders of these shell companies pitch their names or expertise in certain industries; once they have raised a certain amount of money they have a specific amount of time, typically two years, to identify a target. Announced deals are subject to shareholder approval. Finance of America’s services include traditional mortgages, reverse mortgages, commercial-real-estate loans and fixed-income investing. It has grown via a series of acquisitions and over the past roughly five years as a portfolio company of Blackstone’s

Read the rest
Polish e-commerce company Allegro lights up Europe’s IPO market

Polish e-commerce company Allegro lights up Europe’s IPO market

WARSAW/GDANSK, Poland (Reuters) – Shares in Polish e-commerce group Allegro leapt more than 60% on their debut on Monday, giving the company a market value of almost $19 billion in Europe’s biggest initial public offering (IPO) so far this year.

Allegro logo is seen on a smartphone in front of a displayed stock graph in this illustration taken October 12, 2020. REUTERS/Dado Ruvic/Illustration

Founded more than 20 years ago as a home-grown rival to eBay, Allegro is central Europe’s most recognised e-commerce brand and its website is attracting 20 million visitors a month as consumers go online during the COVID-19 pandemic.

Allegro’s strong start mirrored the performance of some recent IPOs in the United States where shares have shot up as investors showed they were willing to pay for companies with potential for growth.

Last month, British e-commerce firm The Hut Group made the biggest debut on the London Stock Exchange in seven years and Allegro’s successful launch was a further sign the European IPO market is picking up.

However, investor appetite seems to be reserved for tech and growth companies – sectors that corporate Europe is light on compared to the United States, where a number of blockbuster tech IPOs have launched this year.

“The recent pandemic highlighted the value of e-commerce for a consumer, and accelerated e-commerce penetration,” said Ivan Kim, an analyst at Xtellus Capital. “Allegro is a well-established marketplace … and is already quite profitable.”

Shares in Allegro closed the day at 70 zlotys, up 63% from their IPO price of 43 zlotys, which was at the upper end of the guidance range.

Allegro immediately became the most valuable company on the Warsaw bourse, which said the company would replace Commerzbank’s mBank in its index of the 20 biggest companies WIG20

Read the rest